Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Insider and Institutional Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 4.5% of Ernexa Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Ernexa Therapeutics and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -1,950.55% | -304.60% |
| Aditxt | -684,001.00% | -461.78% | -80.55% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
Ernexa Therapeutics has a beta of 6.58, meaning that its stock price is 558% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
Earnings and Valuation
This table compares Ernexa Therapeutics and Aditxt”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 4.03 | -$44.54 million | ($3.01) | -0.10 |
| Aditxt | $130,000.00 | 2.62 | -$34.45 million | ($1,387.93) | 0.00 |
Aditxt has lower revenue, but higher earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Summary
Ernexa Therapeutics beats Aditxt on 7 of the 11 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
